[S24] Find a way to get into the brain for breakthrough innovations in CNS drug development

Sun. Mar 27, 2022 9:30 AM - 11:30 AM [Room Q] Shirotori Hall (North) (Bldg. 4: 1F)

Organizer: Tomomi Furihata (Sch. Pharm., Tokyo Univ. Pharm. & Life Sci.), Shingo Ito (Fac. Life Sci. Kumamoto Univ.)

The blood-brain barrier (BBB), which is primarily formed by brain microvascular endothelial cells (BMEC), strictly prevents entry of a variety of drugs into the brain from the systemic circulation, and therefore it has long been an obstacle to drug development for central nervous system (CNS) diseases. On the other hand, a new route to brain parenchyma bypassing the BBB has recently been discovered and gained considerable attention regarding its involvement in CNS diseases. With this background in mind, this symposium will summarize cutting-edge BBB and related research as follows: effects of insulin signaling on BBB functions (Dr. Ito, Kumamoto Univ), development of multicellular-spheroidal human BBB models as a promising research tool for CNS drug development (Dr. Morio, TUPLS), development of an antibody-guided BBB penetrating iduronate-2-sulfatase for treatment of Hunter syndrome (Dr. Fukatsu, JCR Pharma), development of cyclodextrin derivatives as therapeutic tools for Alzheimer's disease (Dr. Motoyama, Kumamoto Univ), and roles of the brain lymphatic system in health and disease (Dr. Izuo, Toyama Univ). We hope this symposium will provide a unique opportunity for academic and industry researchers to share and discuss the current status of the new findings, as well as their perspectives and challenges, aiming at moving forward into a new era of CNS drug development.

+Add all to schedule

イントロダクション：伊藤慎悟（熊本大院薬） (9:30 AM - 9:35 AM)

9:35 AM - 9:57 AM

[S24-1] Quantitative proteomics-based research on the identification of transport molecules and pathogenic mechanisms at the blood-brain barrier

○Shingo Ito¹ (1. Fac. Life Sci. Kumamoto Univ.)

9:57 AM - 10:19 AM

[S24-2] Design and evaluation of cyclodextrin derivatives as therapeutic tools for Alzheimer's disease

○Keiichi Motoyama¹ (1. Fac. Life Sci. Kumamoto Univ.)

10:19 AM - 10:41 AM

[S24-3] Brain lymphatic system in health and disease

○Naotaka Izuo¹ (1. Grad. Sch. Pharm. Sci., Univ. Toyama)

10:41 AM - 11:03 AM

[S24-4] A human immortalized cell-based blood-brain barrier spheroid model as a promising research tool for CNS drug development

○Hanae Morio¹, Keita Kitamura^1,2, Ayaka Okamoto¹, Ryo Ito³, Naomi Wakayama⁴, Yoshiyuki Yamaura³, Takafumi Komori⁴, Tomomi Furihata¹ (1. Sch. Pharm., Tokyo Univ. Pharm. & Life Sci., 2. Grad. Sch. Pharmaceut. Sci, Chiba Univ., 3. Ono Pharm. Co., Ltd., 4. Eisai Co. Ltd.)

11:03 AM - 11:25 AM

[S24-5] Pabinafusp Alfa, a blood-brain barrier penetrating enzyme for treatment of mucopolysaccharidosis II - its delivery to central nervous system -

○Tomoki Fukatsu¹, Takafumi Minamimoto², Eiji Yoden¹, Masafumi Kinoshita¹, Chie Seki², Yuji Nagai², Hideto Morimoto¹, Atsushi Imakiire¹, Aya Sugyo², Hisashi Suzuki², Eiji Yoshida², Hiroyuki Sonoda¹ (1. JCR, 2. QST-iQMS)

総合討論：降幡知巳（東京薬大薬） (11:25 AM - 11:30 AM)

Authentication

A password that applicants have been notified of is required to view abstracts.
If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts.
We will reply after confirming that you were a participant.
Thank you for your understanding.